The latest mixed messaging from the National Advisory Committee on Immunization highlights the urgent need for plain language in talking about COVID-19 and other public health issues
Merck Canada and MaRS Announce Winners of the Lung Cancer Innovation Challenge
News provided by
Share this article
Share this article
Challenge participants presented solutions aimed at improving patient outcomes and reducing time between diagnosis and treatment for lung cancer patients
Challenge winners include
the Kingston Health Sciences Centre and the Princess Margaret Cancer Centre, with solutions to help improve timely access to specialized care in rural South Eastern Ontario and accelerate lung cancer diagnosis and treatment through liquid biopsy
KIRKLAND, QC, April 28, 2021 /CNW/ - Merck Canada and MaRS Discovery District (MaRS) are proud to announce the winners of the Lung Cancer Innovation Challenge: the Kingston Health Sciences Centre (KHSC), competition winner and the Princess Margaret Cancer Centre, runner up winner. The competition, which launched in January 2021, challenged Ontario-based innovators to identify, implement and scale solutions that could help
Article content
Advocates across the country are calling on provincial governments to adjust COVID-19 vaccine prioritization so cancer patients receive their second dose within four weeks rather than waiting up to 16 weeks.
Concern over a delayed second dose comes from preliminary data out of the U.K. which found people with solid cancers (a physical tumour) and blood cancers had a much lower antibody response following just one dose of the Pfizer vaccine compared to healthy people. When a second booster was given 21 days later, nearly all solid cancer patients had a much higher antibody response. This means delaying a second dose could prevent patients from having a fuller response to the vaccine and leaves them susceptible to COVID-19 while they wait for their second jab.
New Study: A Ban On Tanning Beds Will Reduce Skin Cancer in Minors
A recent study indicates that a U.S. ban on the use of tanning beds among minors would prevent thousands of cases of melanoma in adolescents and would save millions of dollars in healthcare costs. The findings are published early online in
CANCER, a peer-reviewed journal of the American Cancer Society.
The dangers of Indoor tanning
Indoor tanning has been linked to an increased risk of melanoma, with the highest risk in those who start using tanning beds at a young age. Unfortunately, the use of tanning beds is a common practice among U.S. adolescents.
E-Mail
A recent study indicates that a U.S. ban on the use of tanning beds among minors would prevent thousands of cases of melanoma in adolescents and would save millions of dollars in healthcare costs. The findings are published early online in
CANCER, a peer-reviewed journal of the American Cancer Society.
Indoor tanning has been linked to an increased risk of melanoma, with the highest risk in those who start using tanning beds at a young age. Unfortunately, the use of tanning beds is a common practice among U.S. adolescents.
Despite the risk of indoor tanning, only a handful of countries have implemented policies to ban tanning beds. Such bans have the potential to save lives and treatment-related costs but come with costs of policy implementation and enforcement, as well as lost revenue to the tanning industry.